Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2009

Open Access 01-12-2009 | Review

Progress and challenges in the vaccine-based treatment of head and neck cancers

Author: Aldo Venuti

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2009

Login to get access

Abstract

Head and neck (HN) cancer represents one of the most challenging diseases because the mortality remains high despite advances in early diagnosis and treatment. Although vaccine-based approaches for the treatment of advanced squamous cell carcinoma of the head and neck have achieved limited clinical success, advances in cancer immunology provide a strong foundation and powerful new tools to guide current attempts to develop effective cancer vaccines. This article reviews what has to be rather what has been done in the field for the development of future vaccines in HN tumours.
Literature
1.
Wiemann B, Starnes CO: Coley's toxins, tumour necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994, 64: 529-64.CrossRef
2.
Monji M, Senju S, Nakatsura T, Yamada K, Sawatsubashi M, Inokuchi A, Nishimura Y: Head and neck cancer antigens recognized by the humoral immune system. Biochem Biophys Res Commun. 2002, 294: 734-741.CrossRef
3.
Wu AA, Niparko KJ, Pai SI: Immunotherapy for head and neck cancer. J Biomed Sci. 2008, 15: 275-89. Epub 2008 Apr 5. Review.CrossRef
4.
Leibowitz MS, Nayak JV, Ferris RL: Head and neck cancer immunotherapy: clinical evaluation. Curr Oncol Rep. 2008, 10: 162-9. Review.CrossRef
5.
Whiteside TL: Anti-tumour vaccines in head and neck cancer: targeting immune responses to the tumour. Curr Cancer Drug Targets. 2007, 7: 633-42. Review.CrossRef
6.
Badaracco G, Venuti A: Human papillomavirus therapeutic vaccines in head and neck tumours. Expert Rev Anticancer Ther. 2007, 7: 753-66. Review.CrossRef
7.
Venuti A, Badaracco G, Rizzo C, Mafera B, Rahimi S, Vigili M: Presence of HPV in head and neck tumours: high prevalence in tonsillar localization. J Exp Clin Cancer Res. 2004, 23: 561-6.
8.
Roden R, Wu TC: How will HPV vaccines affect cervical cancer?. Nat Rev Cancer. 2006, 6: 753-76.CrossRef
9.
Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B: Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res. 2005, 11: 2552-2560.CrossRef
10.
Dominiecki ME, Beatty GL, Pan ZK, Neeson P, Paterson Y: Tumour sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumour model for HPV-transformed tumours. Cancer Immunol Immunother. 2005, 54: 477-488.CrossRef
11.
Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, Ferrone S, Ferris RL: Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol. 2006, 176: 3402-3409.CrossRef
12.
Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL: A uniquesubset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediatessuppression in the tumour microenvironment. Clin Cancer Res. 2007, 13: 4345-4354.CrossRef
13.
Bai A, Higham E, Eisen HN, Wittrup KD, Chen J: Rapid tolerization of virus-activated tumour-specific CD8+ T cells in prostate tumours of TRAMP mice. Proc Natl Acad Sci USA. 2008, 105: 13003-8. Epub 2008 Aug 22.CrossRef
14.
Whiteside TL, Parmiani G: Tumour-infiltrating lymphocytes: Their phenotype, functions and clinical use. Cancer Immunol Immunother. 1994, 39: 15-21.CrossRef
15.
Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients withmetastatic melanoma. Proc Natl Acad Sci USA. 2003, 100: 8372-8377.CrossRef
16.
Ribas A, Camacho L, Lopez-Berestein G, et al: Antitumour activity in melanoma and anti-self responses in phase 1 trial with anti-cytotoxis T lymphocyte associated antigen 4 monoclonal antibody. J Clin Oncol. 2005, 23: 8968-CrossRef
17.
Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN: Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumour immunity. Cancer Res. 2006, 66: 4904-12.CrossRef
18.
Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S: Treatment of advanced tumours with agonistic anti-GITR mAb and its effects on tumour-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med. 2005, 202: 885-91.CrossRef
19.
Tuyaerts S, Van Meirvenne S, Bonehill A, Heirman C, Corthals J, Waldmann H, Breckpot K, Thielemans K, Aerts JL: Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. J Leukoc Biol. 2007, 82: 93-105.CrossRef
20.
Hanabuchi S, Watanabe N, Wang YH, Ito T, Shaw J, Cao W, Qin FX, Liu YJ: Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumour necrosis factor receptor-ligand (GITRL). Blood. 2006, 107: 3617-3623.CrossRef
21.
Marshall E: Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery. Science. 2006, 311: 1688-9.CrossRef
22.
Kim JW, Ferris RL, Whiteside TL: Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. Clin Cancer Res. 2005, 11: 7901-7910.CrossRef
23.
Tomson TT, Roden RB, Wu TC: Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Investig Drugs. 2004, 5: 1247-1261.
24.
Tao MH, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature. 1993, 362: 755-758.CrossRef
25.
Chen TT, Tao MH, Levy R: Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol. 1994, 153: 4775-4787.
26.
Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997, 186: 1623-1631.CrossRef
27.
Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E: Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med. 1997, 3: 849-854.CrossRef
28.
Massa S, Franconi R, Brandi R, Muller A, Mett V, Yusibov V, Venuti A: Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine. 2007, 25: 3018-3021.CrossRef
29.
Venuti A, Massa S, Mett V, Dalla Vedova L, Paolini F, Franconi V, Yusibov V: An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine. 2009.
30.
Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA: Targeting p53 as a general tumour antigen. Proc Natl Acad Sci USA. 1995, 92: 11993-11997.CrossRef
31.
DeLeo AB: p53-based immunotherapy of cancer. Crit Rev Immunol. 1998, 18: 29-35.CrossRef
32.
Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside TL, DeLeo AB: Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res. 1999, 5: 1281-1288.
33.
Gurunathan S, Klinman DM, Seder RA: DNA vaccines: immunology, application, and optimization. Annu Rev Immunol. 2000, 18: 927-974.CrossRef
34.
Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S: Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002, 20: 621-667.CrossRef
35.
Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A Toll-like receptor recognizes bacterial DNA. Nature. 2000, 408: 740-745.CrossRef
36.
Moniz M, Ling M, Hung CF, Wu TC: HPV DNA vaccines. Front Biosci. 2003, 8: 55-68. Review.CrossRef
37.
Massa S, Simeone P, Muller A, Benvenuto E, Venuti A, Franconi R: Antitumour activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther. 2008, 19: 354-64.CrossRef
38.
O'Malley BW, Li D, McQuone SJ, Ralston R: ombination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope. 2005, 115: C391-404.CrossRef
39.
Ling M, Wu TC: Therapeutic human papillomavirus vaccines. Cervical cancer: from etiology to prevention. Edited by: Rohan TE, Shah KV. 2004, Boston: Kluwer Academic Publishers, 345-376.CrossRef
40.
Souders NC, Sewell DA, Pan ZK, Hussain SF, Rodriguez A, Wallecha A, Paterson Y: Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumour in a transgenic mouse model of cancer. Cancer Immun. 2007, 7: 2-12.
41.
Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK, Inglis SC: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 1996, 347: 1523-1527.CrossRef
42.
Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, Lipetz C, Evans AS, Mason M: Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine. 2001, 19: 2549-2556.CrossRef
43.
Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H: Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 2002, 8: 3676-3685.
44.
Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL: mmunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res. 2003, 63 (18): I6032-6041.
45.
Baldwin PJ, Burg van der SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA, Sterling JC: Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res. 2003, 9: 5205-5213.
46.
Davidson EJ, Faulkner RL, Sehr P, Pawlita M, Smyth LJ, Burt DJ, Tomlinson AE, Hickling J, Kitchener HC, Stern PL: Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine. 2004, 22: 2722-2729.CrossRef
47.
Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, Calzado P, Reyes L, Posternak R, Morosoli G, Verde ML, Rosales R: Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther. 2004, 15: 421-431.CrossRef
48.
Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, Contreras ML, Padilla S, Guzman CC, Jimenez R, Reyes L, Morosoli G, Verde ML, Rosales R: Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther. 2006, 13: 592-597.CrossRef
49.
Albarran YCA, de la Garza A, Cruz Quiroz BJ, Vazquez Zea E, Diaz Estrada I, Mendez Fuentez E, Lopez Contreras M, Andrade-Manzano A, Padilla S, Varela AR, Rosales R: MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. BioDrugs. 2007, 21: 47-59.CrossRef
50.
Franconi R, Venuti A: HPV Vaccines in Plants: an appetising solution to Control Infection and Associated Cancers. Papillomavirus research: from Natural History to Vaccines and Beyond. Edited by: Saveria Campo M. 2006, Norfolk, U.K.: Caister Academic Press, 357-372.
51.
Hood EE, Woodard SL, Horn ME: Monoclonal antibody manufacturing in transgenic plants – myths and realities. Curr Opin Biotechnol. 2002, 13: 630-635.CrossRef
52.
McCormick AA, Kumagai MH, Hanley K, Turpen TH, Hakim I, Grill LK, Tusè D, Levy S, Levy R: Rapid production of specific vaccines for lymphoma by expression of the tumour-derived single-chain Fv epitopes in tobacco plants. Proc Natl Acad Sci USA. 1999, 96: 703-708.CrossRef
53.
McCormick AA, Reinl SJ, Cameron TI, Vojdani F, Fronefield M, Levy R, Tusè D: Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumour Ig. J Immunol Methods. 2003, 278: 95-104.CrossRef
54.
Verch T, Yusibov V, Koprowski H: Expression and assembly of a full-length monoclonal antibody in plants using a plant-virus vector. J Immunol Methods. 1998, 220: 69-75.CrossRef
55.
Verch T, Hooper DC, Kiyatkin A, Steplewski Z, Koprowski H: mmunization with a plant-produced colorectal cancer antigen. Cancer Immunol Immunother. 2004, 53: 92-99.CrossRef
56.
Franconi R, Di Bonito P, Dibello F, Accardi L, Muller A, Cirilli A, Simeone P, Donà G, Venuti A, Giorgi C: Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumour protection. Cancer Research. 2002, 62: 3654-58.
57.
Son Y, Mailliard R, Watkins S, Lotze M: Strategies for antigen loading of dendritic cells to enhance the antitumour immune response. Cancer Res. 2002, 62: 1884-1889.
58.
Weng W, Czerwinski D, Timmerman J, Hsu F, Levy R: Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004, 22: 4717-4724.CrossRef
59.
Redfern C, Guthrie T, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF: Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol. 2006, 24: 3107-3112.CrossRef
60.
Ferrara A, Nonn M, Sehr P, Schreckenberger C, Pawlita M, Durst M, Schneider A, Kaufmann AM: Dendritic cellbased tumour vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol. 2003, 129: 521-530.CrossRef
61.
Jaffee EM, Pardoll DM: Considerations for the clinical development of cytokine gene-transduced tumour cell vaccines. Methods. 1997, 12: 143-153.CrossRef
62.
Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of anti-tumour immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992, 71: 1093-1102.CrossRef
63.
Townsend SE, Allison JP: Tumour rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993, 259: 368-370.CrossRef
64.
Eberlein T, Rosenstein M, Rosenberg S: Regression of a disseminated syngeneic solid tumour by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med. 1982, 156: 385-397.CrossRef
65.
Rosenberg S, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumourinfiltrating lymphocytes. Science. 1986, 233: 1318-1321.CrossRef
66.
Overwijk W, Tsung A, Irvine K, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP: gp100/pmel 17 is a murine tumour rejection antigen: Induction of self reactive, tumouricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998, 188: 277-286.CrossRef
67.
Rosenberg S, Terry W: Passive immunotherapy of cancer in animals and man. Adv Cancer Res. 1977, 25: 323-CrossRef
68.
Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of patients with metastatic melanoma with autologous tumour-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994, 86: 1159-1166.CrossRef
69.
Yee C, Thompson J, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000, 192: 1637-1644.CrossRef
70.
Dudley M, Wunderlich J, Nishimura M, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001, 24: 363-373.CrossRef
71.
Dudley M, Wunderlich J, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA: A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002, 25: 243-251.CrossRef
72.
North R: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumour depends on elimination of tumour-induced suppressor T cells. J Exp Med. 1982, 155: 1063-1074.CrossRef
73.
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA: Cancer regression and autoimmunity in patients after clonal repopulation with antitumour lymphocytes. Science. 2002, 298: 850-854.CrossRef
74.
Robbins P, Dudley M, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ, Rosenberg SA: Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004, 173: 7125-7130.CrossRef
75.
Dudley M, Wunderlich J, Yang J, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005, 23: 2346-2357.CrossRef
76.
Imai K, Takaoka A: Comparing antibody and smallmolecule therapies for cancer. Nat Rev Cancer. 2006, 6: 714-727.CrossRef
77.
Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H: Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer. 2007, 120: 781-787.CrossRef
78.
Modjtahedi H, Moscatello DK, Box G, Green M, Shotton C, Lamb DJ, Reynolds LJ, Wong AJ, Dean C, Thomas H, Eccles S: Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer. 2003, 105: 273-280.CrossRef
79.
Modjtahedi H: Molecular therapy of head and neck cancer. Cancer Metastasis Rev. 2005, 24: 129-146.CrossRef
80.
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006, 354: 567-578.CrossRef
81.
Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007, 25: 3712-3718.CrossRef
82.
Caponigro F, Formato R, Caraglia M, Normanno N, Iaffaioli RV: Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumours. Curr Opin Oncol. 2005, 17: 212-217.CrossRef
83.
Leach DR, Krummel MF, Allison JP: Enhancement of antitumour immunity by CTLA-4 blockade. Science. 1996, 271: 1734-1736.CrossRef
84.
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004, 364: 1757-CrossRef
85.
Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU, Proof of Principle Study Investigators: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002, 347: 1645-1651.CrossRef
86.
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer. 1981, 47: 207-14.CrossRef
87.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst. 2000, 92: 205-16.CrossRef
88.
Rosenberg S, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004, 10: 909-15.CrossRef
89.
Nagorsen D, Thiel E: Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res. 2006, 12: 3064-9.CrossRef
90.
Mocellin S, Mandruzzato S, Bronte V, Marincola FM: Cancer vaccines: pessimism in check. Nat Med. 2004, 10: 1278-80.CrossRef
91.
Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol. 2003, 21: 335-376.CrossRef
92.
Strome SE, Chen L: Costimulation-based immunotherapy for head and neck cancer. Curr Treat Options Oncol. 2004, 5: 27-33.CrossRef
93.
Rosenberg SA: Overcoming obstacles to the effective immunotherapy of human cancer. Proc Natl Acad Sci USA. 2008, 105: 12643-4. Epub 2008 Aug; 27.CrossRef
94.
Lappin M, Weiss J, Delattre V, Mai B, Dittmar H, Maier C, Manke K, Grabbe S, Martin S, Simon JC: Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology. 1999, 98: 181-188.CrossRef
95.
Kudo-Saito C, Schlom J, Hodge J: Induction of an antigen cascade by diversified subcutaneous/intratumoural vaccination is associated with antitumour responses. Clin Cancer Res. 2005, 11: 2416-2426.CrossRef
96.
Tagawa S, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS: Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. Cancer. 2003, 98: 144-154.CrossRef
97.
Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ: Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol. 2003, 21: 3826-3835.CrossRef
98.
Williams T, Ynagimoto J, Mazumder A, Wiseman C: IL-2 increases the antibody response in patients receiving autologous intralymphatic tumour cell vaccine immunotherapy. Mol Biother. 1992, 4: 66-69.
Metadata
Title
Progress and challenges in the vaccine-based treatment of head and neck cancers
Author
Aldo Venuti
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2009
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-28-69

Other articles of this Issue 1/2009

Journal of Experimental & Clinical Cancer Research 1/2009 Go to the issue

Research

CHOP5'UTR-c.279T>C and +nt30C>T variants are not associated with overweight condition or with tumors/cancer in Italians – a case-control study

Research

SELDI-TOF MS profiling of serum for detection of nasopharyngeal carcinoma

Review

Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis

Research

Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review

Research

Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo

Research

Expression and biological significance of c-FLIP in human hepatocellular carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits